MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exc ...

Transaction positions Nuwellis to expand into real-time kidney function monitoring and strengthen its long-term cardiorenal platform, subject to customary closing conditionsMINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered into a Securities Purchase Agreement to acquire all of the issued and outstanding capital stock of Rendiatech Ltd., an Is ...

MINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026. Ms. Field is the Chief Executive Officer of ISpecimen Inc., where she oversees performance improvement and the redevelopment of the proprietary software platform. Prior to serving as Chief Executive Officer sh ...

Core Insights - Nuwellis, Inc. has received a notice of allowance for a new patent related to advanced safety mechanisms for blood return line clamps in extracorporeal blood filtration systems, specifically for the Vivian Pediatric Continuous Renal Replacement Therapy (CRRT) System [1][3] - The patented technology enhances safety by dynamically adjusting clamping force based on environmental factors and improving material stability through thermal insulation [2] - The company emphasizes its commitment to pediatric innovation and safety, with a growing portfolio of intellectual property supporting the Vivian system [3][4] Company Overview - Nuwellis, Inc. is a medical technology company focused on solutions for patients with cardio-renal conditions, headquartered in Minneapolis with a subsidiary in Ireland [6] - The company is dedicated to transforming the lives of patients suffering from fluid overload through innovative therapies, including the Aquadex SmartFlow system [6][7] Product Details - The Aquadex SmartFlow system is designed for ultrafiltration therapy in patients with fluid overload, indicated for both temporary and extended use in adults and pediatric patients weighing 20 kg or more [7] - The Vivian system is a pediatric CRRT platform designed for neonates and children, featuring integrated sensors for real-time monitoring and multiple therapy options [8]

Core Viewpoint - Nuwellis, Inc. has announced a postponement of its 2025 second quarter earnings release and conference call, originally set for August 12, 2025, due to the need for additional time to complete valuations and audit procedures [1] Company Overview - Nuwellis, Inc. is a medical technology company focused on fluid management, specifically targeting patients suffering from fluid overload [3] - The company is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [3] Product Information - The Aquadex SmartFlow® system is designed for ultrafiltration therapy, providing a clinically proven method to remove excess fluid from patients with hypervolemia [4] - The system is indicated for temporary use (up to 8 hours) or extended use (longer than 8 hours) in adult and pediatric patients weighing 20 kg or more, whose fluid overload is unresponsive to medical management [4] Upcoming Events - A conference call and webcast to discuss financial results and provide a general business update is scheduled for 9:00 AM ET on August 14, 2025 [1]